IDENTIFYING POLICY VIOLATING VIDEOS BASED ON USER BEHAVIOR

A mechanism is proposed for identifying policy violating videos based on user behavior. A content item service may identify a first video associated with a first probability value for the first video of violating one or more policies set within a content item service platform. The content item service may identify a plurality of other videos that have been co-watched with the first video using a co-watch graph. The content item service may calculate a score for the first video based on probability values for the plurality of other videos of violating the one or more policies and likelihood values for the plurality of other videos of being watched with the first video. The content item service may determine whether to initiate remedial actions regarding the first video based on the score

Constructing the profitable conversation : a semiotic analysis of the company blog as a form of advertising

This project is an examination of the practise of web logging, or “blogging” by companies as a new form of advertising. The essay consists of a semiotic content analysis of three companies’ blog postings over a seven-month period. The goal of the analysis is to illustrate how companies communicate with consumers online has changed due to the emergence of the company blog. The analysis is framed within the aims and history of mass media advertising in North America, as well as the norms associated with blogging as an online communication format

Development of multiplexed real-time quantitative polymerase chain reaction assay for detecting human adenoviruses.

Adenoviruses (AdVs) have been associated with a wide variety of human disease and are increasingly recognized as viral pathogens that can cause significant morbidity and mortality in immunocompromised patients. Early detection of AdV DNA in plasma and sterile fluids has been shown to be useful for identifying patients at risk for invasive AdV disease. Because of the large number of existing Adv types, few real-time quantitative AdV polymerase chain reaction (PCR) assays published effectively cover all AdV types. We designed a series of AdV PCR primers and probes and empirically multiplexed them into 2 separate real-time PCR assays to quantitatively detect all 49 serotypes of human AdV (types 1-49) available from American Type Culture Collection. We then subsequently multiplexed all the primers and probes into 1 reaction. The sensitivity of these assays was determined to be less than 10 copies per reaction (500 copies/mL plasma). In a retrospective evaluation, we detected all 84 clinical AdV isolates isolated in cell culture from patients undergoing hematopoietic stem cell transplantation between 1981 and 1987. Prospective analysis of 46 consecutive clinical samples submitted for AdV testing showed greater sensitivity and equal specificity of the AdV PCR than viral culture. This real-time PCR assay allows rapid, sensitive, and specific quantification of all currently defined AdVs into either 2 or 1 multiplex assay for clinical samples

Fluency Assistance Device (FAD): Masker Upgrades

Around seventy million people internationally have a stutter, a form of a fluency disorder. Some fluency assistance devices are available to the public, but most are highly expensive or unreliable. The Fluency Assistive Device (FAD) team seeks to assist a niche community of these individuals who currently rely on a device known originally as the Edinburgh Masker by partnering with Dave Germeyer. Utilizing his expertise in repairing the Edinburgh Masker, FAD is developing two new versions of the masker to increase its portability, functionality, and cost-effectiveness. The first is an update of the original called the Analog Masker (Version 1.1). A prototype of the Analog Masker v1.1 has been developed, tested and is currently being revised based on the results. Revisions include updating the layout of the board and finalizing the power supply circuitry. The second version, known as the Digital Masker (Version 1.0), will use a Bluetooth-enabled microcontroller to achieve masker functionality. Bluetooth audio output for the Digital Masker has been tested, and two algorithms have been created for the masking output. The supporting software for the Digital Masker is nearing completion. The schematic and the layout design have been started for future implementation of the hardware.https://mosaic.messiah.edu/engr2021/1005/thumbnail.jp

Banner News

https://openspace.dmacc.edu/banner_news/1438/thumbnail.jp

The Grizzly, February 21, 2008

Administration Speaks Out About New Member Education • Rethinking Equality in America • Brought to a Grinding Halt: Reactions to NME Ban • Vending, Vending Everywhere: New Machines to Arrive for Students • Exploring the Circumcision Decision: Benefits and Risks • The Mysterious White Van: Science in Motion at Ursinus • Jasmine: For Those Willing to Spend a Buck or Two • Ursinus Hosts Award-Winning Poet • Professor Victor Brown: Making a Prominent Impact • Alumni Advice for UC Students • Opinions: The Harvard Effect: Will Ursinus Increase Financial Aid to Stay Competitive?; The Fair Tax • Men\u27s Basketball 16-0 in Conference • Glory Days • National Guard Honors Ursinus Rugby Teams • Cosmic Sucker-Punch: The Ultimate Teamhttps://digitalcommons.ursinus.edu/grizzlynews/1756/thumbnail.jp

Salience in Second Language Acquisition: Physical Form, Learner Attention, and Instructional Focus

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/139842/1/fpsyg-07-01284.pd

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

PURPOSE In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety outcomes. PATIENTS AND METHODS Patients with previously untreated unresectable stage III or stage IV melanoma were randomly assigned 1:1:1 to receive nivolumab 1 mg/kg plus ipilimumab 3 mg/kg once every 3 weeks (four doses) followed by nivolumab 3 mg/kg once every 2 weeks (n = 314), nivolumab 3 mg/kg once every 2 weeks (n = 316), or ipilimumab 3 mg/kg once every 3 weeks (four doses; n = 315). Coprimary end points were progression-free survival and overall survival (OS) with nivolumab plus ipilimumab or nivolumab versus ipilimumab. Secondary end points included objective response rate, descriptive efficacy assessments of nivolumab plus ipilimumab versus nivolumab alone, and safety. Melanoma-specific survival (MSS; descriptive analysis), which excludes deaths unrelated to melanoma, was also evaluated. RESULTS Median OS (minimum follow-up, 6.5 years) was 72.1, 36.9, and 19.9 months in the combination, nivolumab, and ipilimumab groups, respectively. Median MSS was not reached, 58.7, and 21.9 months, respectively; 6.5-year OS rates were 57%, 43%, and 25% in patients with BRAF-mutant tumors and 46%, 42%, and 22% in those with BRAF–wild-type tumors, respectively. In patients who discontinued treatment, the median treatment-free interval was 27.6, 2.3, and 1.9 months, respectively. Since the 5-year analysis, no new safety signals were observed. CONCLUSION These 6.5-year CheckMate 067 results, which include the longest median OS in a phase III melanoma trial reported to date and the first report of MSS, showed durable, improved clinical outcomes with nivolumab plus ipilimumab or nivolumab versus ipilimumab in patients with advanced melanoma and, in descriptive analyses, with the combination over nivolumab monotherapy

Long-Baseline Neutrino Facility (LBNF) and Deep Underground Neutrino Experiment (DUNE) Conceptual Design Report Volume 2: The Physics Program for DUNE at LBNF

The Physics Program for the Deep Underground Neutrino Experiment (DUNE) at the Fermilab Long-Baseline Neutrino Facility (LBNF) is described